Strengthening Canada’s Biomanufacturing Ecosystem
Today we celebrate nearly one year since the groundbreaking of the Critical Medicines Production Centre (CMPC). Located in the Life Sciences Campus at the Edmonton Research Park, the CMPC is a key component of the Canadian Critical Drug Initiative (CCDI)
The Canadian Critical Drug Initiative is a nearly $200 million project we lead in partnership with the University of Alberta, to build an integrated research, commercialization and manufacturing cluster for our life sciences sector. Backed by the Government of Alberta and federal investment through PrairiesCan in March 2023, this milestone marked a pivotal step toward strengthening Canada’s domestic biomanufacturing capacity.
The Critical Medicines Production Centre is the only Canadian facility of its kind with integrated high volume production capacity. During a crisis, it can scale an injectable, small molecule or biologic product for the entire country in a critical 100-day sprint. It will secure domestic supply resilience and also position Canada as a leading biomanufacturing hub through its flexible commercial production capabilities. This will attract foreign investment and increase the production of Canadian-made medicines.
Why Canada Needs Domestic Drug Production
The COVID-19 pandemic highlighted the need for robust domestic production. While the pandemic is behind us, supply chains are still disrupted, making the need for the CMPC’s manufacturing capacity more critical than ever. Facilities like the Critical Medicines Production Centre (CMPC) are vital to building a more resilient, self-sufficient biomanufacturing ecosystem. They can respond rapidly to public health crises, supply chain shocks or future emergencies.
At the same time, economic uncertainty and shifting global politics are changing how essential goods are produced and accessed. By expanding domestic manufacturing capacity, Canada will not only secure reliable access to life-saving medicines but also drive innovation and attract global investment. The CMPC will open new export opportunities and position Canada as a hub for biomanufacturing.
CCDI: A Transformative Investment in Canada’s Biomanufacturing Strategy
The CCDI represents a nearly $200 million commitment to building a thriving life sciences cluster. In partnership with the University of Alberta, this initiative secures Canada’s access to essential medicines while fostering innovation and expanding our biomanufacturing capabilities. The CCDI is enabling:
- Critical Medicines Manufacturing – The CMPC will produce sterile injectables and other essential medicines for hospitals and emergency care. This includes drugs like Propofol, a critical anesthetic influencing surgery efficiency and patient wait times.
- Rapid Emergency Response – The CMPC will have a sprint production capacity to supply medicines for the entire country in just 100 days, allowing it to deliver rapid manufacturing during public health crises and supply chain disruptions.
- Support Research & Commercialization – Collaboration with the University of Alberta and key infrastructure upgrades will support more company incubation programs. It will also produce small-batch clinical material production for Canadian researchers and pharmaceutical companies to bring new drugs to market.
- Drive Economic Growth & Workforce Development – The initiative itself has created over 350 high-quality jobs, and the site will serve as a hub for hands-on training and workforce development, enabling more future jobs and talent attraction.
CMPC: Canada’s Most Advanced Drug Manufacturing Facility
The CMPC is equipped with state-of-the-art biomanufacturing technology to support both drug substance and drug product manufacturing. It focuses on small-molecule API production and aseptic fill/finish capabilities. It features formulation vessels capable of producing clear solutions, emulsions and suspensions, ensuring flexibility in drug manufacturing. Key features include:
- Sterile Injectable Production – High-throughput manufacturing for vials (1-20 mL) and bottles (20-100 mL) with a Canada-wide capacity.
- Fully Automated, Robotic Filling Lines – Advanced isolator-based technology ensuring precision, low rejection rates and high regulatory compliance.
- Aseptic Processing & Terminal Sterilization – Featuring a rotating autoclave for specialized sterilization of suspensions and emulsions. It also has an additional autoclave for terminal sterilization, ensuring product safety and stability across multiple formulations.
- Flexible Packaging & Storage Solutions – Automated inspection ensures quality control with visual defect identification and container closure integrity testing. The packaging line supports various carton sizes and eco-trays, while warehouse capabilities include cold storage and freezing options for diverse needs.
- Integrated Microbiology Laboratory – The facility is designed to support sterile production, featuring isolator-based sterile testing, environmental monitoring and quality assurance systems to maintain GMP compliance and ensure product integrity.
“With world-class aseptic fill/finish and small-molecule API production, the CMPC will set a new standard for pharmaceutical manufacturing in Canada. It’s equipped with cutting-edge technology and advanced automation for precision, efficiency and scalability. We’re providing essential manufacturing infrastructure to drive life sciences innovation forward.” – Hans Bauer, VP of Technical Operations
Expanding Innovation at the Life Sciences Campus
The CCDI has enabled the development of a comprehensive Life Sciences Campus within the Edmonton Research Park. The CMPC is one of several key facilities that accelerates company growth.
The CCDI is also expanding the Biotechnology Business Development Centre (BBDC), another key facility on the Life Sciences Campus. Expansions to this facility include:
- Enhanced Scale-Up Incubation – Renovated, furnished offices, collaborative spaces, programming and access to experts for life sciences companies transitioning beyond early-stage incubation.
- Warehousing – The BBDC is home to warehousing operations for critical import and export logistics.
- Future Production Capacity – Active Pharmaceutical Ingredient (API) production capabilities, with comprehensive testing for chemicals, APIs, finished drug products, and emulsions.
- Advanced Chemical Production – Support advanced chemical production, enabling small-molecule manufacturing for R&D, clinical trials and GMP production. This expansion will include specialized equipment and a dedicated R&D lab for process development.
The CCDI tackles the gaps identified in Canada’s Biomanufacturing and Life Sciences Strategy—turning policy into real production capability
Looking Ahead: A Global Biomanufacturing Hub
The CCDI funding represented a fundamental shift in Canada’s approach to biomanufacturing strategy in Canada. It fosters an environment where life sciences innovation can thrive from early discovery through to commercial manufacturing. By integrating research, commercialization, and pharmaceutical production within a Life Sciences Campus cluster, we are not only securing Canada’s supply of essential medicines but also positioning the country as a global leader in life sciences innovation.
We offer life sciences innovators access to world-class infrastructure, expertise, and support to bring novel treatments to market. As we expand this ecosystem, we remain committed to supporting biomanufacturing in Canada and innovators improving health outcomes worldwide.
With continued collaboration from the provincial and federal government, industry and academic partners, Alberta and Canada are poised to become a world-class hub for biomanufacturing and life sciences excellence.
” The CMPC is a cornerstone of Canada’s biomanufacturing future, creating hundreds of high-quality jobs and strengthening our life sciences ecosystem. By fostering innovation, securing domestic pharmaceutical production and attracting top talent, we are not just building a facility—we are laying the foundation for a globally competitive life sciences hub. “ – Andrew MacIsaac, CEO of API